A disciplined, milestone-driven layout. Early discovery, validation, and patent protections have been successfully completed through targeted self-funding.
We successfully isolated the core sequence-driven molecular lock-and-key architecture and confirmed selective intracellular activation in tissue cultures under dark (light-independent) environments.
To establish defense-in-depth, we secured early priority dates through comprehensive global patent filings covering both composition genus scales and sequential delivery methodologies.
Our immediate scientific priority is scaling quantitative cell-line experiments to replicate, catalogue, and publish standard dose-response and selectivity profiles across target degenerative cell types.
Non-invasive multi-frequency dielectric spectroscopy hardware for real-time tissue-level Cellular Expression Failure mapping and precise exogenous trigger delivery. Fully offline with integrated proprietary payload uptake monitoring. Currently in advanced calibration and frequency alignment, soon ready for field-testing.
Because our mechanism leverages well-characterized primary components, development splits naturally into distinct pathways based on existing real-world signals and theoretical modeling.
Upon accumulation of validated in-vitro data we will advance IND-enabling work on core assets while selectively divesting non-core portfolio projects through out-licensing or strategic sale.